ALK inhibitor 2ALK inhibitor, novel and selective CAS# 761438-38-4 |
- LDK378
Catalog No.:BCC3691
CAS No.:1032900-25-6
- LDN193189 Hydrochloride
Catalog No.:BCC1695
CAS No.:1062368-62-0
- AP26113
Catalog No.:BCC1069
CAS No.:1197958-12-5
- SB525334
Catalog No.:BCC2531
CAS No.:356559-20-1
- TAE684 (NVP-TAE684)
Catalog No.:BCC3660
CAS No.:761439-42-3
- (R)-Crizotinib
Catalog No.:BCC1284
CAS No.:877399-52-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 761438-38-4 | SDF | Download SDF |
PubChem ID | 66577032 | Appearance | Powder |
Formula | C23H28ClN7O3S | M.Wt | 518.03 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 50 mg/mL (96.52 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | 2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-N-methylbenzenesulfonamide | ||
SMILES | CNS(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCN(CC4)C)OC | ||
Standard InChIKey | NURCYJBMLKNYHB-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C23H28ClN7O3S/c1-25-35(32,33)21-7-5-4-6-19(21)27-22-17(24)15-26-23(29-22)28-18-9-8-16(14-20(18)34-3)31-12-10-30(2)11-13-31/h4-9,14-15,25H,10-13H2,1-3H3,(H2,26,27,28,29) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | ALK inhibitor 2 is a novel and selective inhibitor for the ALK kinase. References: |
ALK inhibitor 2 Dilution Calculator
ALK inhibitor 2 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.9304 mL | 9.652 mL | 19.3039 mL | 38.6078 mL | 48.2598 mL |
5 mM | 0.3861 mL | 1.9304 mL | 3.8608 mL | 7.7216 mL | 9.652 mL |
10 mM | 0.193 mL | 0.9652 mL | 1.9304 mL | 3.8608 mL | 4.826 mL |
50 mM | 0.0386 mL | 0.193 mL | 0.3861 mL | 0.7722 mL | 0.9652 mL |
100 mM | 0.0193 mL | 0.0965 mL | 0.193 mL | 0.3861 mL | 0.4826 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
ALK inhibitors are potential anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK [1]. As the same as ALK inhibitor 1, ALK inhibitor 2 is a novel and selective inhibitor for the ALK kinase as well.
In vitro: ALK inhibitor 2 (2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino] pyrimidin-4-yl]amino]-N-methylbenzenesulfonamide) is a chemical analogue of LDK378 that is a potent ALK inhibitor [2].
In vivo: No animal in-vivo data available currently.
Clinical trial: Currently ALK inhibitor 2 is only in the preclinical developlent stage and no clinical data are available.
Reference:
[1] Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009;420(3):345-61.
[2] Marsilje TH, Pei W, Chen B, Lu W, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013;56(14):5675-90.
- TAE226 (NVP-TAE226)
Catalog No.:BCC3885
CAS No.:761437-28-9
- ALK inhibitor 1
Catalog No.:BCC1339
CAS No.:761436-81-1
- Ipragliflozin
Catalog No.:BCC5137
CAS No.:761423-87-4
- Glucosylvitexin
Catalog No.:BCN5929
CAS No.:76135-82-5
- 8-Hydroxy-DPAT hydrobromide
Catalog No.:BCC6681
CAS No.:76135-31-4
- 7-Hydroxy-DPAT hydrobromide
Catalog No.:BCC6756
CAS No.:76135-30-3
- Phaseollidin hydrate
Catalog No.:BCN3962
CAS No.:76122-57-1
- Solithromycin
Catalog No.:BCC6446
CAS No.:760981-83-7
- Hederacoside D
Catalog No.:BCN2330
CAS No.:760961-03-3
- Enalapril maleate
Catalog No.:BCC8955
CAS No.:76095-16-4
- SCH 28080
Catalog No.:BCC7154
CAS No.:76081-98-6
- Artocarpin
Catalog No.:BCN4309
CAS No.:7608-44-8
- TAE684 (NVP-TAE684)
Catalog No.:BCC3660
CAS No.:761439-42-3
- Mildronate
Catalog No.:BCC2289
CAS No.:76144-81-5
- TCPOBOP
Catalog No.:BCC6979
CAS No.:76150-91-9
- Derrone
Catalog No.:BCN4587
CAS No.:76166-59-1
- Piptocarphin F
Catalog No.:BCN6447
CAS No.:76215-53-7
- 5-Deoxycajanin
Catalog No.:BCN4310
CAS No.:7622-53-9
- Ehretinine
Catalog No.:BCN1994
CAS No.:76231-29-3
- 15-Hydroxyferruginol
Catalog No.:BCN3294
CAS No.:76235-93-3
- Piptocarphin A
Catalog No.:BCN4586
CAS No.:76248-63-0
- Yukovanol
Catalog No.:BCN3699
CAS No.:76265-12-8
- Fmoc-Lys(Tfa)-OH
Catalog No.:BCC3524
CAS No.:76265-69-5
- Fmoc-Met(O)-OH
Catalog No.:BCC3530
CAS No.:76265-70-8
Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor.[Pubmed:26235945]
Bioorg Med Chem Lett. 2015 Sep 15;25(18):3992-8.
A series of novel 2,4-diaminopyrimidine compounds bearing bicyclic aminobenzazepine were synthesized and evaluated for their anti-ALK activities. The activities of these compounds were confirmed in both enzyme- and cell-based ALK assays. Amongst compounds synthesized, KRCA-0445 showed very promising results in pharmacokinetic study and in vivo efficacy study with H3122 xenograft mouse model.
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.[Pubmed:24819116]
J Med Chem. 2014 Jun 12;57(11):4720-44.
Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-positive non-small-cell lung carcinoma patients, progression during treatment eventually develops. Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation. In addition, some patients progress due to cancer metastasis in the brain. Using structure-based drug design, lipophilic efficiency, and physical-property-based optimization, highly potent macrocyclic ALK inhibitors were prepared with good absorption, distribution, metabolism, and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability. These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clinically reported ALK kinase domain mutations. Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms. This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.[Pubmed:23742252]
J Med Chem. 2013 Jul 25;56(14):5675-90.
The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are described. In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684). Compound 15b is currently in phase 1 and phase 2 clinical trials with substantial antitumor activity being observed in ALK-positive cancer patients.
Importance of protein flexibility in ranking inhibitor affinities: modeling the binding mechanisms of piperidine carboxamides as Type I1/2 ALK inhibitors.[Pubmed:25644934]
Phys Chem Chem Phys. 2015 Feb 28;17(8):6098-113.
Anaplastic lymphoma kinase (ALK) has gained increased attention as an attractive therapeutic target for the treatment of various cancers, especially non-small-cell lung cancer (NSCLC). Recently, piperidine carboxamides were reported as Type I1/2 inhibitors of ALK, which occupy both the ATP binding site and the back ATP hydrophobic cavity in DFG-in conformation. Due to the dynamic behavior of ALK in the binding of Type I1/2 inhibitors, the accurate predictions of the binding structures and relative binding potencies of these inhibitors are quite challenging. In this study, different modeling techniques, including molecular docking, ensemble docking based on multiple receptor conformations, molecular dynamics simulations and free energy calculations, were utilized to explore the binding mechanisms of piperidine carboxamides. Our predictions show that the conventional docking protocols are not sufficient to predict the relative binding potencies of the studied inhibitors with high accuracy, but incorporating protein flexibility before or after docking is quite effective to improve the prediction accuracy. Notably, the binding free energies predicted by MM/GBSA or MM/PBSA based on the MD simulations for the docked poses give the highest correlation with the experimental data, highlighting the importance of the inclusion of receptor flexibility for the accurate predictions of the binding potencies for Type I1/2 inhibitors of ALK. Furthermore, the comprehensive analysis of several pairs of representative inhibitors demonstrates the importance of hydrophobic interactions in improving the binding affinities of the inhibitors with the hot-spot residues surrounding the binding pocket. This work is expected to provide valuable clues for further rational design of novel and potent Type I1/2 ALK inhibitors.